Subsequent to the third quarter of 2025, Burcon made continued significant progress in its strategic initiatives. The Company successfully scaled up commercial production of its pea protein isolate, marking a pivotal milestone in its go-to-market strategy. This scale up was accomplished at the Company’s Galesburg facility and took less than 90 days. The truncated timeframe enables Burcon to meet customer demand and unlock revenue opportunities. This pea protein market is expected to have a TAM of approximately US$215M to US$392M.